ライフサイエンスコーパス: BMD

1 BMD and geometry-specific dietary patterns were identifi

2 BMD by dual-energy x-ray absorptiometry, 25-hydroxyvitam

3 BMD decreased significantly in the year after critical i

4 BMD is caused by in-frame mutations in the gene encoding

5 BMD was not different across quartiles of protein intake

6 BMD, bone width, section modulus (SM; reflecting bending

7 hen, in a single-arm, open-label trial in 11 BMD patients and a double-blind, placebo-controlled cros

8 associated variants, and the BMD-GRS with 50 BMD-associated variants.

9 y eQTL and bioinformatic approaches among 56 BMD loci from our previous GWAS meta-analysis.

10 e (n = 31,800) and femoral neck (n = 32,961) BMD, and from the arcOGEN consortium for three OA phenot

11 provide support for the use of the DDM as a BMD equivalent methodology that will enable hospital-bas

12 Each additional BMD lowering allele of the genetic risk score was associ

13 (n = 97) had significantly greater adjusted BMD decline than controls (n = 614) during the first 96

14 Genotype data from the 63 adult BMD associated SNPs were investigated individually and a

15 n HIV, HIV disease characteristics, ART, and BMD.

16 ositively associated with total-body BMC and BMD at age 20 y [covariate-adjusted increments of 40.7-5

17 ctory had 3.2-3.4% higher total body BMC and BMD than those who were in the "consistently lower" traj

18 n intakes, which account for 1-8% of BMC and BMD variances.

19 Body length, BMC and BMD, but not body mass, are rescued by infection of two-

20 measured clinical characteristics, BTMs, and BMD during admission and 1 year after ICU discharge.

21 n between protein intake (grams per day) and BMD, ALM, appendicular lean mass normalized for height (

22 d dilated cardiomyopathy, as well as DMD and BMD female carriers.

23 Moreover, patients with DMD and BMD who develop end-stage heart failure may benefit from

24 e mutations, L54R and L172H, causing DMD and BMD, respectively, in full-length dystrophin.

25 dual-energy x-ray absorptiometry (DXA), and BMD by quantitative computed tomography (QCT) were asses

26 expressed on ischemic tissue endothelium and BMD-EPC act as double-locks to secure targeted EPC- endo

27 ly to induce ischemic tissue endothelium and BMD-EPC to express both E-selectin and its ligands.

28 We computed the Fx-GRS with 16 fracture- and BMD-associated variants, and the BMD-GRS with 50 BMD-ass

29 ted to study the association between KTR and BMD/BMSi/trabecular bone score.

30 previously identified SNPs in these loci and BMD, while nominally significant in sequenced participan

31 first systematic overlap analysis of OA and BMD on a genome wide scale.

32 atic evaluation of pleiotropy between OA and BMD, highlight genes with biological relevance to both t

33 the genetic variants shared between PBC and BMD.

34 A exon sequencing of two cell lines (TMD and BMD) derived from a mouse xenograft model.

35 um, and 25-hydroxyvitamin D), and annualized BMD reduction over a 8-year follow-up of 692 middle-aged

36 ndronate the year before screening; an areal BMD T score of -2.5 or lower at the total hip, femoral n

37 tage change from baseline in total hip areal BMD was 2.6% (95% CI 2.2 to 3.0) in the romosozumab grou

38 was percentage change from baseline in areal BMD by dual-energy x-ray absorptiometry at the total hip

39 thnic genome-wide association study of areal BMD (aBMD) and bone mineral content (BMC) Z-scores measu

40 ) is a primary contributor to TDF-associated BMD decline in this age group.

41 aily RCE intake over 1 y potently attenuated BMD loss caused by estrogen deficiency, improved bone tu

42 In analyses stratified by baseline BMD status, parathyroidectomy was associated with reduce

43 y BMD test year, and longer interval between BMD test and parental hip fracture diagnosis.

44 months correlated with change in total body BMD (r = 0.35, P = .02).

45 l hip (TH), femoral neck (FN), or total body BMD or bone biomarkers.

46 tion-to-treat analysis, mean (SD) whole-body BMD z score by dual x-ray absorptiometry improved by 0.2

47 ed to phenotypic resistance as determined by BMD and by commercial methods during routine patient car

48 growth of H. influenzae and S. pneumoniae by BMD).

49 n, serum, and lung surfactant was studied by BMD.

50 ne, and polysorbate 80 levels were tested by BMD and DD.

51 ray absorptiometry (DXA), entered a clinical BMD registry, and were followed using linked administrat

52 Sixty-six patients completed BMD testing.

53 In contrast, BMD cells formed a spheroid with a smoother and more cir

54 in overweight and obese men did not decrease BMD at any anatomical site or alter cortical and trabecu

55 = 0.0001, P = 1.24 x 10(-38))] and decreased BMD acquisition from 9 to 17 years (P = 9.17 x 10(-7)).

56 ) to determine areal bone mineral densities (BMDs), and (c) quantitative CT with dedicated three-dime

57 Condylar bone mineral density (BMD) (computed tomography Hounsfield unit [CT HU]) and b

58 dy length, and reduced bone mineral density (BMD) and content (BMC) first evident during postnatal de

59 aracterized by reduced bone mineral density (BMD) and disrupted bone architecture, predisposing the p

60 s) identified multiple bone mineral density (BMD) and fracture-associated loci.We conducted a study t

61 L) are at risk for low bone mineral density (BMD) and frail health, outcomes potentially modifiable b

62 e risk, despite normal bone mineral density (BMD) and high BMI-factors that are generally protective

63 lain most variation in bone mineral density (BMD) and hip bone geometry are associated with fracture

64 ssociated with reduced bone mineral density (BMD) and increased fracture rates, particularly in women

65 luding measurements of bone mineral density (BMD) and novel bone markers in adult patients with CKD-5

66 ssociated with loss of bone mineral density (BMD) and risk of bone fractures is undetermined.

67 cancer may develop low bone mineral density (BMD) any time before or after diagnosis.

68 eral content (BMC) and bone mineral density (BMD) are positively correlated with dietary protein inta

69 ng to lower volumetric bone mineral density (BMD) at both distal radius and tibia in patients with he

70 l fractures as well as bone mineral density (BMD) at the lumbar spine, total hip, femoral neck, and o

71 thy army recruits, and bone mineral density (BMD) by Dual X-Ray Absorptiometry (DXA) and repeated aft

72 bone turnover markers, bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA), and BMD

73 Bone mineral density (BMD) changes and fracture rate.

74 We compared adjusted bone mineral density (BMD) changes between human immunodeficiency virus (HIV)-

75 t on lumbar spine (LS) bone mineral density (BMD) compared with lower protein intake (net percentage

76 Little is known about bone mineral density (BMD) during pregnancy.

77 ge change in total hip bone mineral density (BMD) from baseline to week 48 in the as-treated populati

78 eps strength (QS), and bone mineral density (BMD) in 2986 men and women, aged 19-72 y, from the Frami

79 (SNPs) associated with bone mineral density (BMD) in adults.

80 WL) negatively affects bone mineral density (BMD) in older populations and has specifically been show

81 rrelate with decreased bone mineral density (BMD) in untreated HIV infection.

82 versus teriparatide on bone mineral density (BMD) in women with postmenopausal osteoporosis transitio

83 Background: Bone mineral density (BMD) is a heritable phenotype that predicts fracture ris

84 und: Whether change in bone mineral density (BMD) is an accurate indicator of antifracture effect in

85 High bone mineral density (BMD) is associated with an increased risk of developing

86 gnificantly attenuated bone mineral density (BMD) loss at the L2-L4 lumbar spine vertebra (P < 0.05),

87 oflavone therapies and bone mineral density (BMD) loss in peri- and postmenopausal women.We systemati

88 Bone mineral density (BMD) measured by dual-energy x-ray absorptiometry is use

89 p fracture in a unique bone mineral density (BMD) registry linked to administrative databases spannin

90 eral content (BMC) and bone mineral density (BMD) was assessed using DXA.

91 eral content (BMC) and bone mineral density (BMD) were measured at age 20 y through the use of dual-e

92 e turnover markers and bone mineral density (BMD) were performed at weeks 0, 12, 24, and 48 weeks.

93 cardiovascular health, bone mineral density (BMD), and physical fitness.

94 porosis, assessed from bone mineral density (BMD), as a new potential target of intervention, or whet

95 ortical and trabecular bone mineral density (BMD), BMC, and bone area at the 4% tibia and anthropomet

96 tive associations with bone mineral density (BMD), bone area, and bone mineral content (BMC) in a coh

97 Offspring total body bone mineral density (BMD), bone mineral content (BMC), and bone area (BA) wer

98 ve control in terms of bone mineral density (BMD), fractures, and safety in patients with CKD.

99 ng fracture, improving bone mineral density (BMD), or preventing or delaying osteoporosis in men with

100 status biomarkers and bone mineral density (BMD), risk of osteoporosis, and biomarkers of bone turno

101 minishing weight loss, bone mineral density (BMD), trabecular thickness, trabecular separation and tr

102 e people have a higher bone mineral density (BMD), which suggests that low 25(OH)D may not be associa

103 s are also involved in bone mineral density (BMD).

104 with 2% to 6% loss of bone mineral density (BMD).

105 rily by measurement of bone mineral density (BMD).

106 n for reduced skeletal bone mineral density (BMD).

107 and femoral neck (FN)-bone mineral density (BMD).

108 dy summary datasets of bone mineral density (BMD).

109 gnificant decreases in bone mineral density (BMD).

110 ariables to changes in bone mineral density (BMD).

111 oclast differentiating factor and diminishes BMD.

112 ognized cases of Borrelia miyamotoi disease (BMD) in North America were reported in the northeastern

113 Decreases in DXA BMD were observed when aromatization was suppressed but

114 into less severe Becker muscular dystrophy (BMD) by altering pre-mRNA splicing to restore an open re

115 Becker muscular dystrophy (BMD) is a progressive X-linked muscle wasting disease fo

116 strophy (DMD) and Becker muscular dystrophy (BMD), interventions reducing the progression of myocardi

117 strophy (DMD) and Becker muscular dystrophy (BMD), X-linked dilated cardiomyopathy, as well as DMD an

118 of patients with Becker muscular dystrophy (BMD, n = 14) and limb-girdle type 2I muscular dystrophy

119 ed male sex, northern rural residence, early BMD test year, and longer interval between BMD test and

120 ation and homing of bone marrow-derived EPC (BMD-EPC).

121 esolution for assessment of proximal femoral BMD.

122 ures; there was insufficient evidence for FN BMD and overall fractures.Current evidence shows no adve

123 n and men with extreme low femoral neck (FN) BMD.

124 the only signal marginally replicated for FN-BMD (P = 5.08 x 10(-3)) at alpha = 0.10/11 = 9.09 x 10(-

125 only signal significantly replicated for FN-BMD (P = 7.55 x 10(-6)) at alpha = 0.05/2 = 0.025 in gen

126 940 and PRR5 rs3213550 as top signals for FN-BMD (P = 7.67 x 10(-6) and 1.58 x 10(-5)) in gender-comb

127 d III-replicated signal attaining GWS for FN-BMD (P = 8.87 x 10(-12)).

128 hese findings describe a novel mechanism for BMD-EPC homing and indicate that dual E-selectin/ligand

129 identified several significant pathways for BMD [false discovery rate (FDR) < 0.05], such as KEGG FO

130 All participants were referred for BMD testing, which may limit generalizability.

131 r lean body mass was associated with greater BMD loss at both lumbar spine and hip.

132 In the crossover group, BMD increased from extension baseline by 16.5% at the lu

133 In the long-term group, BMD increased from FREEDOM baseline by 21.7% at the lumb

134 ded in the study, 70 had DMD (92%) and 6 had BMD (8%); mean (SD) age at baseline was 13.1 (4.4) years

135 ted with lower fracture risk because of high BMD, high bending strength, and more stable bones.

136 , and dairy pattern was associated with high BMD, high SM, low BR, and low risk of fractures [HR (95%

137 : 0.44, 0.81) but not in women with a higher BMD-GRS.We observed significant effects of CaD intake on

138 action between placebo assignment and higher BMD-GRS: quartiles 2-3, PRERI = 0.03; quartile 4, PRERI

139 BC level was associated with higher BMD loss over time at multiple anatomical sites, includi

140 The decline in hip BMD (n = 115 for MVC, n = 109 for TDF) at week 48 was le

141 ch patients, romosozumab led to gains in hip BMD that were not observed with teriparatide.

142 on: Treatment-related increases in total hip BMD are associated with reduced fracture risk compared w

143 omen with a detectable decrease in total hip BMD compared with stable BMD had an absolute increase of

144 serial bone density examinations, total hip BMD increased transiently in women with parathyroidectom

145 CD14 were associated with greater total hip BMD loss, whereas markers of CD4(+) T-cell senescence an

146 etric BMD, cortical thickness, and total hip BMD those with stage 0-2 fibrosis.

147 omen with a detectable increase in total hip BMD was 1.3% (CI, 0.4% to 2.2%) and 2.6% (CI, 0.7% to 4.

148 quartile range) percent decline in total hip BMD was greater in those with high- compared to low- exp

149 eeks, the percentage of decline in total hip BMD was smaller in the vitamin D3 plus calcium group tha

150 Both bisphosphonates and denosumab improve BMD in men with nonmetastatic prostate cancer who are re

151 vent vertebral fractures but may not improve BMD (low SOE).

152 Denosumab improved BMD and reduced the incidence of new radiographic verteb

153 stically significant difference in change in BMD between exercise and usual care.

154 Measurements: Change in BMD between the first and second dual-energy x-ray absor

155 We compared change in BMD to age- and sex-matched control subjects from the Ge

156 ive evidence describing long-term changes in BMD after critical illness is needed to further define t

157 0 nmol/L) was not associated with changes in BMD or BMC.

158 ment had no significant effect on changes in BMD that occurred between 12-20 wk of gestation and 0-14

159 (GRM3) gene gained a premature stop codon in BMD cells, and silencing GRM3 in TMD cells altered their

160 perience a significantly greater decrease in BMD in the year after admission compared with population

161 Despite persistent decrease in BMD, trabecular microarchitecture and tissue quality rem

162 mpared with stable BMD, whereas decreases in BMD are associated with greater risk for fractures.

163 l but statistically significant decreases in BMD by week 24 that inversely correlated with TFV-DP, wi

164 ncreases in bone resorption and decreases in BMD in men.

165 s in LGMD2I, which are severely disrupted in BMD.

166 TAP, neither of which has been implicated in BMD or BMC previously.

167 e original trial, and continued increases in BMD without plateau.

168 A relationship was still severely lowered in BMD, but was almost normalized in LGMD2I.

169 asoregulatory actions of sarcolemmal nNOS in BMD patients, and constitutes a putative novel therapy f

170 47) or exons 45 to 48 (Delta45-48) result in BMD in 97% (36 of 37) of subjects.

171 lopment of osteoporosis and the variation in BMD.

172 nd RANKL expressions in cartilage, increased BMD, BV/TV, and decreased Tb.Sp in subchondral bone.

173 Also, despite increased BMD at some sites when maintaining excess body weight, c

174 Bisphosphonates were effective in increasing BMD, but no trial was sufficiently powered to detect red

175 decoy receptor for RANKL, thereby increasing BMD.

176 al resolution of more than 10 000 individual BMD data points on a typical archived prosthetic hip sca

177 ociated with hypertension, dyslipidemia, low BMD, and slow walking; and both deficits, independently,

178 ty percent of survivors met criteria for low BMD, and 18.6% for frailty/prefrailty.

179 After adjusting for body mass index, low BMD was associated with GHD (odds ratio [OR], 1.59; 95%

180 style and hormonal deficits with risk of low BMD and frailty among survivors of ALL.

181 ormonal deficits to minimize the risk of low BMD and frailty.

182 The low BMD observed in younger MSM remains unexplained and need

183 ith the lowest genetic predisposition to low BMD.

184 d tomography of L1 through L2 vertebrae; low BMD was defined as an age- and sex-standardized z score

185 h hormone (GHD) and/or sex steroids with low BMD and frailty.

186 Pediatric cancer survivors with low BMD may benefit from low-magnitude, high-frequency mecha

187 loss, and tooth loss are associated with low BMD.

188 genetic risk score was associated with lower BMD at age 13 [per allele effect size, 0.002 g/cm(2) (SE

189 A causal relation of hsCRP with lower BMD was not evident in this study.

190 ure risk was observed in women in the lowest BMD-GRS quartile (HR: 0.60, 95% CI: 0.44, 0.81) but not

191 pport an effect of protein with Ca+/-D on LS BMD, TH BMD, or forearm fractures; there was insufficien

192 f BMD during pregnancy.We evaluated maternal BMD during pregnancy as a function of vitamin D status i

193 Mean BMD of the femoral neck (0.88 g/cm2; 95% CI, 0.84-0.91 g

194 The standard broth microdilution method (BMD) is demanding and requires expertise.

195 Illumina MiSeq WGS and broth microdilution (BMD) assays were performed on 90 bloodstream isolates of

196 ed to that of reference broth microdilution (BMD) during the testing of 64 strains enriched for presu

197 titute (CLSI) reference broth microdilution (BMD) for 99 isolates of Pseudomonas aeruginosa, 26 Acine

198 Broth microdilution (BMD), macrodilution (MD), and agar dilution (AD) methods

199 Monitoring BMD in clinical practice may help to identify women with

200 CI, 13.25-13.51 g; P = .03) and femoral neck BMD (0.87 g/cm2; 95% CI, 0.74-0.83 g/cm2 vs 0.91 g/cm2;

201 The means +/- SDs of femoral neck BMD loss were -0.02 +/- 0.05 and 0.0 +/- 0.03 g/cm(2) fo

202 ual maturity, anthropometry and femoral neck BMD Z-score to control confounding effects.

203 sociated with a greater loss of femoral neck BMD.

204 Net BMD loss by week 24 in participants with TFV-DP levels i

205 a cortical width more than 4 mm had a normal BMD in 90% of the cases.

206 SD; 95% CI: -0.20, -0.03; P = 0.009) but not BMD.

207 D/SD; 95% CI: 0.03, 0.22; P = 0.010) but not BMD.

208 .No significant differences in the change of BMD, BMC, or bone area for the total-body radius, lumbar

209 lts implicate GPC6 as a novel determinant of BMD, and also identify abnormal skeletal phenotypes in k

210 of widened, unstable bones, independently of BMD.

211 showed that bisphosphonates may slow loss of BMD among transplant recipients (moderate SOE), but thei

212 struments now permit the safe measurement of BMD during pregnancy.We evaluated maternal BMD during pr

213 Serial measures of BMD and weight were not used.

214 Subsequently, the rate of BMD decline slowed in HIV-infected individuals but remai

215 ) prevented denervation-induced reduction of BMD further supporting our hypothesis that denervation-i

216 to a large genome wide association study of BMD.

217 tered their spheroid shape closer to that of BMD cells.

218 itek 2 performance was comparable to that of BMD for testing a limited number of Enterobacteriaceae c

219 itek 2 performance was comparable to that of BMD using both Vitek 2 breakpoints and 2016 CLSI M100S 2

220 he presence of MAT led to underestimation of BMD, and this bias increased with increasing MAT content

221 wed a significantly (P < 0.01) higher WMD of BMD change of 0.01 (95% CI: 0.00, 0.02) compared with th

222 01) higher weighted mean difference (WMD) of BMD change of 0.01 (95% CI: 0.01, 0.02) than the control

223 Effects of teriparatide and denosumab on BMD and fractures are unclear (very low SOE), and these

224 cy non-coding variants have large effects on BMD and fracture, thereby providing rationale for whole-

225 gh-sensitivity C-reactive protein (hsCRP) on BMD at the forearm, femoral neck, and lumbar spine.

226 Effects of osteoporosis medications on BMD, fracture risk, and safety among patients with CKD a

227 ons among patients with CKD; and reported on BMD, fractures, or safety (mortality and adverse events)

228 We report the effect of FTC/TDF on BMD in HIV-seronegative men who have sex with men and in

229 Although there were positive trends on BMD at most bone sites, only the LS showed moderate evid

230 enters included 76 male patients with DMD or BMD undergoing 2 CMR studies with a 2-year interval for

231 nsurance registrations, and the provincewide BMD registry.

232 itivity and specificity in detecting reduced BMD, respectively, of 0.789 (SE 0.031; 95% CI, 0.721-0.8

233 Objective: To evaluate repeated BMD testing as an indicator of treatment-related fractur

234 and bone mineral density genetic risk score (BMD-GRS) modify the association between the intake of ca

235 We evaluated 72 genome-wide significant BMD SNPs for association with PBC using two European GWA

236 gnificant racial/ethnic differences in spine BMD.

237 longer had significantly lower lumbar spine BMD (0.89 g/cm2; 95% CI, 0.85-0.93 g/cm2 vs 0.94 g/cm2;

238 -13.51 g; P = .02), as was mean lumbar spine BMD (0.90 g/cm2; 95% CI, 0.87-0.94 g/cm2 vs 0.94 g/cm2;

239 phenotype (hip and/or knee) and lumbar spine BMD (rg=0.18, P = 2.23 x 10-2), which may be driven by t

240 ly reported common variants for lumbar spine BMD (rs11692564(T), MAF = 1.6%, replication effect size

241 for change in femoral neck and lumbar spine BMD and across a range of subgroup analyses.

242 The ZOL arm had an 8% higher lumbar spine BMD at 12 weeks relative to the placebo arm (P = .003),

243 Lumbar spine BMD decline was also less with MVC (median -0.88% vs -2.

244 HLA-DR(+)) were associated with lumbar spine BMD loss.

245 m diagnosis, with whole-body or lumbar spine BMD z scores of -1.0 or lower.

246 African Americans lost more spine BMD than did Caucasians (-0.04 +/- 0.04 compared with -0

247 QCT spine BMD fell substantially in all testosterone-dose groups i

248 ely correlated with TFV-DP, with more stable BMD thereafter.

249 crease in total hip BMD compared with stable BMD had an absolute increase of 2.9% (95% CI, 1.5% to 4.

250 h reduced fracture risk compared with stable BMD, whereas decreases in BMD are associated with greate

251 nitiation independently predicted subsequent BMD loss.

252 locus exert opposing effects TB-LM and TBLH-BMD, and have a stronger association with the former tra

253 al-body less head bone mineral density (TBLH-BMD) regions in 10,414 children.

254 eritability is 43% (95% CI: 34-52%) for TBLH-BMD, and 39% (95% CI: 30-48%) for TB-LM, with a shared g

255 effect of protein with Ca+/-D on LS BMD, TH BMD, or forearm fractures; there was insufficient eviden

256 Clinicians should be aware that BMD measurements underestimate fracture risk in people w

257 acture- and BMD-associated variants, and the BMD-GRS with 50 BMD-associated variants.

258 icant multiplicative interaction between the BMD-GRS and CaD assignment (P-interaction = 0.01).

259 Limitation: Lack of standardization in the BMD testing interval.

260 3 plus calcium supplementation mitigates the BMD loss seen with initiation of efavirenz/emtricitabine

261 s and 136 non-Aspergillus isolates) with the BMD and Etest methods.

262 associated with bone geometry in addition to BMD might influence risk of fractures.

263 Compared to BMD cells, TMD cells exhibited higher cellular motility.

264 erminations were statistically equivalent to BMD.

265 famSKAT have been reported to be related to BMD or osteoporosis in the literature.

266 cal failure load was obtained by using total BMD (r(2) = 0.73, P < .001) and trochanteric BMD (r(2) =

267 evaluating isoflavone therapies for treating BMD loss at the lumbar spine and femoral neck in estroge

268 BMD (r(2) = 0.73, P < .001) and trochanteric BMD (r(2) = 0.80, P < .001).

269 ckgrounds.A total of 301 women who underwent BMD measurements at 12-20 wk of gestation and again at 0

270 Using BMD as the gold standard, our genotypic resistance predi

271 Volumetric BMD was measured with and without correction for MAT.

272 Changes in areal and volumetric BMD and bone biomarkers were compared by analysis of var

273 urations, the best model combined volumetric BMD and a moment of inertia (r(2) = 0.78, P < .001; r(2)

274 volumetric BMD (-0.85), cortical volumetric BMD (-0.67), cortical area (-0.61), and cortical thickne

275 incipal component analysis of the volumetric BMD and bone microstructure indicated that trabecular bo

276 ower mean z scores for trabecular volumetric BMD (-0.85), cortical volumetric BMD (-0.67), cortical a

277 Trabecular volumetric BMD was lower in coinfected than in HCV- or HIV-monoinfe

278 ower mean z scores for trabecular volumetric BMD, cortical thickness, and total hip BMD those with st

279 n had decreased tibial trabecular volumetric BMD, diminished cortical dimensions, and significant end

280 al analysis software to determine volumetric BMDs and geometric parameters (neck axis length, cortica

281 th factor-23 concentration, and age, whereas BMD of the spine measured by quantitative computed tomog

282 ecting MDA-MB-231 breast cancer cells, while BMD cells were isolated from the metastasized bone.

283 Surprisingly, categorical agreement with BMD was only 47.6%, 57.1%, and 44.6% for the three metho

284 t 14 y of age was positively associated with BMD and BMC at 20 y of age [differences: 8.6 mg/cm(2) (9

285 UK Biobank to identify loci associated with BMD as estimated by quantitative ultrasound of the heel.

286 that were much more strongly associated with BMD compared to the GWAS SNPs.

287 was more strongly negatively associated with BMD in HIV-positive persons with a history of a Centers

288 mon and rare non-coding SNVs associated with BMD independently from GWAS common SNPs, suggesting both

289 t-related characteristic was associated with BMD loss, but lower lean body mass was associated with g

290 ctivation were independently associated with BMD loss.

291 as been shown to be strongly associated with BMD, highlighting the potential of pleiotropy to improve

292 was no longer independently associated with BMD.

293 genes including CRP, was not associated with BMD.

294 endochondral ossification pathway genes with BMD and osteoporosis in postmenopausal Han Chinese women

295 resent study, we report that, in 13 men with BMD, sympatholysis is defective mainly in patients whose

296 n is associated with ALM and QS but not with BMD.

297 Patients with BMD presented with nonspecific symptoms, including fever

298 ords of only 51 of the 97 case patients with BMD were reviewed.

299 , an inverse association of joint score with BMD and failure load suggests the negative role of hemop

300 t included individuals aged >/=40 years with BMD tests and self-reports of parental hip fracture betw